Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
New data presented at the EHA meeting in Stockholm shows a 52% reduction in the risk of death when treated with Jakafi versus BAT. These data are from a continuing 3 year follow-up of the phase III Comfort2 study. Spleen reduction greater than 35% is being achieved in 51.4% of the patients. These results should give prescribing physicians confidence going forward to prescribe Jakafi to less sick patients.
If you look at the actual presentation, the results aren't as dramatic as the topline would suggest. And because this isn't a pre-designated endpoint it doesn't lead to a label claim. As stated, this is the sort of thing that reassures physicians already inclined to prescribe Jakafi. I'm a little concerned about the signal suggesting that people who aren't as well as they feel (aesthenia=weakness) are going out and having accidents. That IS a genuine issue when it happens.
For "The good tj:" survival data on PV?? People don't die anytime soon from PV. And given that Jakafi is an expensive drug usually in competition with bleeding as a PV treatment, it isn't too clear how large the addressable PV market is. My guess is that it's comparable sized to MF. The main issue for both PV and ET is safety, and there simply aren't the patient-years to talk about that with the accuracy that mostly-well people need.
i would say both yes and no, yes it is great for those suffering from MF and no not for the stock, what needs to happens is results like this for PV.... there is just not a large enough DOMESTIC market to drive the sales of MF to push the stock to new levels. the PV market is considerably larger than MF...currently incyte is still over a year away from that point in time